The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Slides:

Advertisements

Similar presentations

1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.

Advertisements

Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.

Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.

SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.

Copyright © 2008 Delmar. All rights reserved. Chapter 21 Populations with Chronic Diseases.

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin (insulin is a hormone that regulates blood sugar) or.

Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon Daniel Bessesen, MD.

Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.

Katy L. Gordon, BSN, RN What are the Statistics? Centers for Disease Control (2009). Adult obesity: Obesity rises among adults.

Therapy of Type 2 Diabetes Mellitus: UPDATE

KORIN M. TRUMPIE Evidence Based Medicine Spring 2009.

Diabetes Mellitus For high school and college students By Emily Freedman A disease that disrupts normal metabolism, interfering with cells’ ability to.

Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.

VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 4 Stan Schwartz MD, FACP, FACE.

IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM (Part 1) Stan Schwartz MD, FACP, FACE.

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM (Part 2) Stan Schwartz MD, FACP, FACE.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.

[START WITH A PATIENT STORY – something compelling that demonstrates the value of diabetes education.] This patient’s story illustrates why I’m passionate.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

CHAPTER 7: Obesity in Women. Introduction 68% of U.S. population is overweight or obese. Resulting medical and psychosocial difficulties can be debilitating.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

Date of download: 5/31/2016 From: Metabolic Risk Factors Worsen Continuously across the Spectrum of Nondiabetic Glucose Tolerance: The Framingham Offspring.

Date of download: 6/2/2016 From: Are Metabolically Healthy Overweight and Obesity Benign Conditions?: A Systematic Review and Meta- analysis Ann Intern.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

Need For Action. Blood glucose levels are higher than normal but not yet diabetes ** 1 in 3 American adults (79 million) have prediabetes Occurs before.

Date of download: 9/17/2016 From: Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive.

From: Screening for Syphilis Infection in Pregnancy: U. S

Prevention Diabetes.

From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):

Chapter 4 Where Are You.

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

Ann Intern Med. 2014;160(11): doi: /M Figure Legend:

From: Pharmacologic Therapy for Type 2 Diabetes Mellitus

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients.

Behavioral Change Strategies Conducive to Reducing Rates of Disease and Disability and Promoting Rehabilitation and Daily Functioning Tina Cloney, PhD,

From: Systematic Review: Strategies for Using Exercise Therapy To Improve Outcomes in Chronic Low Back Pain Ann Intern Med. 2005;142(9): doi: /

From: The Evolving Diabetes Burden in the United States

From: Synopsis of the 2017 U. S. Department of Veterans Affairs/U. S

From: Meta-Analysis: Pharmacologic Treatment of Obesity

Part 5 Stan Schwartz MD, FACP, FACE Private Practice, Ardmore

From: Effect of a Low-Carbohydrate Diet on Appetite, Blood Glucose Levels, and Insulin Resistance in Obese Patients with Type 2 Diabetes Ann Intern Med.

From: Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular DiseaseGrand Rounds Discussion From the Beth Israel Deaconess Medical.

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

Does One Size Fit All in Obesity Management?

Prevention Diabetes Dr Abir Youssef 29/11/2018.

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

Obesity Management.

Presentation transcript:

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program Cardiometabolic Diabetes Center and Affiliate, Main Line Health System Emeritus, Clinical Associate Professor University of Pennsylvania Part 1

Outline Epidemiology and Economics of obesity/diabetes Perspectives on Obesity Consequences of Obesity, Prediabetes, Obesity Obesity/ Diabetes Risk Factors, Obesity/ Diabetes Onset can be Prevented or Delayed – Early Risk Identification and Intervention. Medical Benefits to Weight Loss Treatment- –Basics, Generalities –Obesity Lifestyle- Diet, Activity, Behavior Medications –Weight Control, WEIGHT REDUCTION in DIABETES

- Metabolically Healthy Obese Yes, but…Healthy Obese= OXYMORON

Obesity Paradox: Metabolically Healthy Obese Patients still has Increased CV rates and All Cause mortality And have other adverse outcomes related to DJD and Sleep Apnea, for example

Date of download: 12/14/2013 Copyright © American College of Physicians. All rights reserved. Are Metabolically Healthy Overweight and Obesity Benign Conditions?: NO!! THUS= OXYMORON Ann Intern Med. 2013;159(11): doi: / Meta-analyses of various clinical characteristics, by metabolic–body mass index categories. Data shown as weighted mean difference compared with metabolically healthy normal- weight persons (reference). To convert cholesterol, triglyceride, and glucose values to traditional units (mg/dL), divide by , , and , respectively. HOMA-IR = Homeostasis Model Assessment of Insulin Resistance.* P < 0.05.

Medical Complications of Obesity Phlebitis venous stasis Metabolic Non-metabolic

Outline Epidemiology and Economics of obesity/diabetes Perspectives on Obesity Consequences of Obesity, Prediabetes, Obesity Obesity/ Diabetes Risk Factors, Obesity/ Diabetes Onset can be Prevented or Delayed – Early Risk Identification and Intervention. Medical Benefits to Weight Loss Treatment- –Basics, Generalities –Obesity Lifestyle- Diet, Activity, Behavior Medications –Weight Control, WEIGHT REDUCTION in DIABETES